TFCP2 and familial pancreatic carcinoma: Indeed, FQI1, the inhibitor for TFCP2 exhibited antiproliferative activity in multiple cancer cell lines, suggesting the potential clinical application of FOI1 for the treatment of pancreatic cancer.